Chun-Ping Chang

Chun-Ping Chang

Auto-generated profile, based on publicly available information

Chun-Ping Chang

Institute of Biotechnology and Pharmaceutical Research National Health Research Institutes 35053 Zhunan Miaoli County Taiwan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
TCTing Chen
Ting Chen
CFCheng-Yin Fei
Cheng-Yin Fei
YCYi-Ping Chen
Yi-Ping Chen
KSKaren Sargsyan
Karen Sargsyan
CCChun-Ping Chang
Chun-Ping Chang
CLCarmay Lim
Carmay Lim

19 May 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
YCYa-Hui Chi
Ya-Hui Chi
TYTeng-Kuang Yeh
Teng-Kuang Yeh
YKYi-Yu Ke
Yi-Yu Ke
WLWen-Hsing Lin
Wen-Hsing Lin
CTChia-Hua Tsai
Chia-Hua Tsai
CCChun-Ping Chang
Chun-Ping Chang
The A-type Aurora kinase is upregulated in many human cancers, and it stabilizes MYC-family oncoproteins, which have long been considered an undruggable target. Here, we describe the design and synthesis of a series of pyrimidine-based derivatives able to inhibit Aurora A kinase activity and reduce levels of cMYC and MYCN. Through structure-based drug design of a small molecule that induces the DFG-out conformation of Aurora A kinase, lead compound 13 was identified, which potently (IC50 < 200 nM) inhibited the proliferation of high-MYC expressing small-cell lung cancer (SCLC) cell lines. Pharmacokinetic optimization of 13 by prodrug strategies resulted in orally bioavailable 25, which demonstrated an 8-fold higher oral AUC (F = 62.3%). Pharmacodynamic studies of 25 showed it to effectively reduce cMYC protein levels, leading to >80% tumor regression of NCI-H446 SCLC xenograft tumors in mice. These results support the potential of 25 for the treatment of MYC-amplified cancers including SCLC.

9 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
CCChun-Ping Chang
Chun-Ping Chang
TYTeng-Kuang Yeh
Teng-Kuang Yeh
CCChiung-Tong CHEN
Chiung-Tong CHEN
WWWan-Ping Wang
Wan-Ping Wang
YCYen-Ting Chen
Yen-Ting Chen
YCYa-Hui Chi
Ya-Hui Chi
Aurora kinase inhibitors, such as alisertib, can destabilize MYC-family oncoproteins and have demonstrated compelling antitumor efficacy. In this study, we report 6K465, a novel pyrimidine-based Aurora A inhibitor, that reduces levels of c-MYC and N-MYC oncoproteins more potently than alisertib. In an analysis of the antiproliferative effect of 6K465, the sensitivities of small cell lung cancer (SCLC) and breast cancer cell lines to 6K465 were strongly associated with the protein levels of c-MYC and/or N-MYC. We also report DBPR728, an acyl-based prodrug of 6K465 bearing fewer hydrogen-bond donors, that exhibited 10-fold improved oral bioavailability. DBPR728 induced durable tumor regression of c-MYC- and/or N-MYC-overexpressing xenografts including SCLC, triple-negative breast cancer, hepatocellular carcinoma, and medulloblastoma using a 5-on-2-off or once-a-week dosing regimen on a 21-day cycle. A single oral dose of DBPR728 at 300 mg/kg induced c-MYC reduction and cell apoptosis in the tumor xenografts for more than 7 days. The inhibitory effect of DBPR728 at a reduced dosing frequency was attributed to its uniquely high tumor/plasma ratio (3.6-fold within 7 days) and the long tumor half-life of active moiety 6K465. Furthermore, DBPR728 was found to synergize with the mTOR inhibitor everolimus to suppress c-MYC- or N-MYC-driven SCLC. Collectively, these results suggest DBPR728 has the potential to treat cancers overexpressing c-MYC and/or N-MYC.

29 April 2021 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
TCTing Chen
Ting Chen
CFCheng-Yin Fei
Cheng-Yin Fei
YCYi-Ping Chen
Yi-Ping Chen
KSKaren Sargsyan
Karen Sargsyan
JLJian-Jong Liang
Jian-Jong Liang
CLCarmay Lim
Carmay Lim

4 November 2022 in Bioorganic Chemistry
Verified
Journal Article
Closed access
WHWen-Chi Hsiao
Wen-Chi Hsiao
KHKun-Yi Hsin
Kun-Yi Hsin
ZWZhong-Wei Wu
Zhong-Wei Wu
JSJen-Shin Song
Jen-Shin Song
YYYen-Nan Yeh
Yen-Nan Yeh
MHMing-Shiu Hung
Ming-Shiu Hung

1 January 1991 in Terrestrial, Atmospheric and Oceanic Sciences
Verified
Journal Article
Open access
HLHock Lim
Hock Lim
CCC.-P. Chang
C.-P. Chang
TLTian-Kuay Lim
Tian-Kuay Lim
Several numerical model simulations (Hayashi and Sumi, 1986; Lau and Peng, 1987) reported generation of eastward propagating equatorial disturbances...